Verified-RX Podcast
Oral Arguments: Enlicitide, the first oral PCSK9 inhibitor for dyslipidemia
Cardiovascular disease remains a leading cause of death, while evolving guidelines and increasingly aggressive LDL cholesterol targets are changing how clinicians approach lipid management. Jodi Martinez, Pharmacist Clinical Specialist in Cardiology at the University of Colorado Hospital, part of UCHealth, joins Kerry Schwartz, Senior Clinical Manager for Evidence Based Medicine and Outcomes with the Vizient Center for Pharmacy Practice Excellence, to explore the emerging role of enlicitide in lipid management. They discuss the evidence behind its approval, its potential to expand patient access and where this first oral PCSK9 inhibitor may fit alongside existing therapies.
Guest Speaker:
Dr. Jodi Martinez, Pharm.D., BCPS, BCCP, HF-CERT
Pharmacist Clinical Specialist in Cardiology
University of Colorado Hospital, UCHealth
Host:
Dr. Kerry Schwarz, Pharm.D., MPH
Senior Clinical Manager, Evidence-Based Medicine and Outcomes
Vizient Center for Pharmacy Practice Excellence
Show Notes:
[01:26]
- The limitations of current lipid management and why many high-risk patients still struggle to reach increasingly aggressive LDL cholesterol targets.
- How cost, prior authorization requirements and step therapy can create barriers to accessing injectable PCSK9 therapies.
[03:27]
- The evidence behind enlicitide and findings from the CORALreef clinical trial supporting its FDA approval.
- How enlicitide performed across LDL cholesterol, non-HDL cholesterol, ApoB and lipoprotein(a) endpoints, and why cardiovascular outcomes remain an important unanswered question.
[06:37]
- An oral PCSK9 inhibitor could expand access by offering an alternative to specialty injectable therapies.
- Why retail pharmacy availability, cost and greater prescribing flexibility could help more patients receive intensive lipid lowering therapy.
[08:11]
- The potential barriers to enlicitide adoption, including delays in formulary review, insurance coverage and the administrative burden placed on clinicians.
- The lack of published cardiovascular outcomes could influence payer coverage, formulary placement and early uptake.
[10:15]
- Station remains the cornerstone of lipid management and where enlicitide may ultimately play a role
- Clinicians may consider the amount of LDL reduction a patient needs when choosing among available therapies.
Links and Resources:
Subscribe Today!